Compare
Biolife Solutions Inc vs Outset Medical, Inc. vs Iridex Corp vs Axogen, Inc.
| Latest fiscal year | Biolife Solutions Inc BLFS | Outset Medical, Inc. OM | Iridex Corp IRIX | Axogen, Inc. AXGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-01-03 | 2025-12-31 |
| Revenue | $96.21M | $119.48M | $52.67M | $225.21M |
| Revenue growth (YoY) | +28.9% | +5.1% | +8.2% | +20.2% |
| Gross margin | 64.6% | 39.1% | 36.5% | 74.3% |
| Operating margin | -17.3% | -55.8% | -4.9% | -3.5% |
| Net margin | -4.8% | -68.3% | -8.4% | -7.0% |
| Net income | -$4.59M | -$81.65M | -$4.44M | -$15.70M |
| EPS (Diluted) | -$0.10 | -$5.37 | -$0.26 | -$0.34 |
| Operating cash flow | $20.11M | -$46.33M | -$2.12M | $812.0K |
| Free cash flow | $10.64M | -$47.12M | -$2.26M | -$2.93M |
| Cash & equivalents | $33.04M | $35.01M | $6.03M | $35.55M |
| Total assets | $405.88M | $264.50M | $29.15M | $221.69M |
| Total liabilities | $34.00M | $137.54M | $24.23M | $92.84M |
| Shareholders' equity | $371.89M | $126.95M | $4.92M | $128.85M |
| Return on year-end equity | -1.2% | -64.3% | -90.1% | -12.2% |
| Shares outstanding | 48.20M | 18.17M | 17.31M | 47.20M |
Revenue, most recent five fiscal years
| Fiscal year | Biolife Solutions Inc | Outset Medical, Inc. | Iridex Corp | Axogen, Inc. |
|---|---|---|---|---|
| Latest | $96.21M Ended 2025-12-31 | $119.48M Ended 2025-12-31 | $52.67M Ended 2026-01-03 | $225.21M Ended 2025-12-31 |
| 1 year earlier | $74.65M Ended 2024-12-31 | $113.69M Ended 2024-12-31 | $48.67M Ended 2024-12-28 | $187.34M Ended 2024-12-31 |
| 2 years earlier | $68.02M Ended 2023-12-31 | $130.38M Ended 2023-12-31 | $51.87M Ended 2023-12-30 | $159.01M Ended 2023-12-31 |
| 3 years earlier | $76.24M Ended 2022-12-31 | $115.38M Ended 2022-12-31 | $56.97M Ended 2022-12-31 | $138.58M Ended 2022-12-31 |
| 4 years earlier | $119.16M Ended 2021-12-31 | $102.60M Ended 2021-12-31 | $53.90M Ended 2022-01-01 | $127.36M Ended 2021-12-31 |